Bright Minds Biosciences (DRUG) Receivables - Accured (2025 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Receivables - Accured came in at $714329.9 in Q1 2026, up 476.1% YoY from $123994.7 in Q1 2025, and up 279.93% on a QoQ basis from $188018.6 in Q4 2025.
Bright Minds Biosciences (DRUG) Receivables - Accured (2025 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 2 years of Receivables - Accured data on file, last reported at $714329.9 in Q1 2026.
- Quarterly Receivables - Accured rose 476.1% year-over-year to $714329.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $714329.9 (up 476.1% YoY) and the FY2025 annual result came in at $147618.1, changed N/A from the prior year.
- Receivables - Accured grew to $714329.9 in Q1 2026, from $188018.6 in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $714329.9 in Q1 2026 to a low of $123994.7 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | 714,329.90 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 714,329.90 |
| Mar 31, 2026 | 714,329.90 |
| Dec 31, 2025 | 188,018.59 |
| Dec 31, 2025 | 188,018.59 |
| Sep 30, 2025 | 147,618.08 |
| Sep 30, 2025 | 147,618.08 |
| Mar 31, 2025 | 123,994.68 |
| Mar 31, 2025 | 123,994.68 |